Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Care Facilities

DaVita Inc. provides a variety of health care services. The Company provides kidney dialysis services for patients suffering from chronic kidney failure. DaVita serves patients worldwide.
Website: davita.com



Growth: Pretty weak revenue growth rate 4.7%, there is acceleration compared to average historical growth rates 3.4%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of -11.9%

Profitability: LTM EBITDA margin is positive, +22.0%. On average the margin is improving unsteadily. In the last quarter the company beat the estimated EPS, +9.6%. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.15 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -1.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 124.7% higher than minimum and 17.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.7x by EV / Sales multiple , the company can be 30% undervalued

Insiders: For the last 3 months insiders sold company shares on $147.7 mln (-1.007% of cap.)

Key Financials (Download financials)

Ticker: DVA
Share price, USD:  (+4.7%)147.02
year average price 149.24  


year start price 135.17 2024-03-10

min close price 126.11 2024-04-18

max close price 177.35 2025-02-04

current price 147.02 2025-03-09
Common stocks: 94 600 000

Dividend Yield:  0.0%
FCF Yield LTM: -1.2%
EV / LTM EBITDA: 9.6x
EV / EBITDA annualized: 9.2x
Last revenue growth (y/y):  +4.7%
Last growth of EBITDA (y/y):  +26.3%
Historical revenue growth:  +3.4%
Historical growth of EBITDA:  +11.4%
EV / Sales: 2.1x
Margin (EBITDA LTM / Revenue): 22.0%
Fundamental value created in LTM:
Market Cap ($m): 13 908
Net Debt ($m): 13 191
EV (Enterprise Value): 27 099
Price to Book: 36.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-02-17finbold.com

Here's why this Warren Buffett stock plunged 11% in a day

2025-02-14fool.com

Why DaVita Inc Stock Is Plummeting Today

2025-02-14marketwatch.com

DaVita's stock leads S&P 500 decliners after Berkshire pares stake. Its soft guidance isn't helping.

2025-02-14finbold.com

Here's why Warren Buffett dumped $31 million worth of this stock

2025-02-14cnbc.com

Warren Buffett's Berkshire Hathaway sells some DaVita; Shares fall on disappointing guidance

2025-02-13seekingalpha.com

DaVita Inc. (DVA) Q4 2024 Earnings Call Transcript

2025-02-13zacks.com

DaVita HealthCare (DVA) Beats Q4 Earnings and Revenue Estimates

2025-02-13reuters.com

DaVita forecasts 2025 profit below estimates, shares plummet

2025-02-12zacks.com

DVA Q4 Estimates Unchanged Before Earnings: How to Play the Stock?

2025-02-04zacks.com

DaVita HealthCare (DVA) Increases Yet Falls Behind Market: What Investors Need to Know
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol DVA DVA DVA DVA DVA DVA DVA DVA DVA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066
fillingDate 2024-10-29 2024-08-06 2024-05-02 2024-02-14 2023-11-07 2023-08-03 2023-05-08 2023-02-22 2022-10-31
acceptedDate 2024-10-29 17:04:29 2024-08-06 17:03:37 2024-05-02 16:12:00 2024-02-14 17:01:00 2023-11-07 17:08:38 2023-08-03 17:07:32 2023-05-08 17:03:28 2023-02-22 17:19:41 2022-10-28 18:02:55
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 3 264M 3 187M 3 071M 3 146M 3 121M 3 000M 2 873M 2 917M 2 949M
costOfRevenue 2 152M 2 318M 2 079M 2 334M 2 067M 2 056M 2 058M 2 089M 2 086M
grossProfit 1 112M 869M 992M 812M 1 054M 945M 815M 828M 863M
grossProfitRatio 0.341 0.273 0.323 0.258 0.338 0.315 0.284 0.284 0.293
researchAndDevelopmentExpenses 0 0 0 0 0 0 0 0 0
generalAndAdministrativeExpenses 394M 368M 362M 401M 377M 364M 332M 380M 365M
sellingAndMarketingExpenses 0 9M 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 394M 368M 362M 401M 377M 364M 332M 380M 365M
otherExpenses 183M -27M -13M -5M -20M 1M 178M 194M 194M
operatingExpenses 577M 368M 550M 401M 565M 548M 510M 574M 560M
costAndExpenses 2 732M 2 686M 2 629M 2 735M 2 633M 2 604M 2 568M 2 662M 2 645M
interestIncome 0 0 0 0 126M 0 0 0 0
interestExpense 135M 98M 99M 96M 98M 104M 101M 101M 100M
depreciationAndAmortization 187M 176M 187M 43 812 188M 184M 182M 186M 190M
ebitda 698M 692M 623M 606M 665M 590M 493M 443M 501M
ebitdaratio 0.214 0.212 0.203 0.193 0.213 0.197 0.172 0.152 0.17
operatingIncome 535M 501M 484M 411M 496M 405M 312M 256M 312M
operatingIncomeRatio 0.164 0.157 0.158 0.131 0.159 0.135 0.108 0.088 0.106
totalOtherIncomeExpensesNet -161M -135M 29M -122M -12M 2M -97M -109M -105M
incomeBeforeTax 373M 371M 372M 289M 378M 295M 215M 147M 207M
incomeBeforeTaxRatio 0.114 0.117 0.121 0.092 0.121 0.098 0.075 0.051 0.07
incomeTaxExpense 78M 72M 66M 58M 69M 49M 44M 34M 43M
netIncome 215M 223M 240M 151M 247M 179M 171M 113M 165M
netIncomeRatio 0.066 0.07 0.078 0.048 0.079 0.06 0.059 0.039 0.056
eps 2.56 2.56 2.73 1.67 2.7 1.96 1.89 1.26 1.81
epsdiluted 2.5 2.5 2.65 1.62 2.62 1.91 1.85 1.23 1.77
weightedAverageShsOut 84M 87M 88M 90M 91M 91M 90M 90M 91M
weightedAverageShsOutDil 86M 89M 91M 93M 94M 93M 92M 92M 93M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol DVA DVA DVA DVA DVA DVA DVA DVA DVA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066
fillingDate 2024-10-29 2024-08-06 2024-05-02 2024-02-14 2023-11-07 2023-08-03 2023-05-08 2023-02-22 2022-10-31
acceptedDate 2024-10-29 17:04:29 2024-08-06 17:03:37 2024-05-02 16:12:00 2024-02-14 17:01:00 2023-11-07 17:08:38 2023-08-03 17:07:32 2023-05-08 17:03:28 2023-02-22 17:19:41 2022-10-28 18:02:55
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 1 071M 503M 345M 465M 449M 327M 317M 244M 368M
shortTermInvestments 21M 21M 11M 12M 12M 12M 50M 78M 74M
cashAndShortTermInvestments 1 092M 524M 356M 476M 461M 340M 367M 322M 442M
netReceivables 2 631M 2 733M 2 991M 2 416M 2 378M 2 367M 2 382M 2 551M 2 493M
inventory 129M 127M 146M 143M 110M 110M 107M 109M 107M
otherCurrentAssets 185M 170M 105M 103M 91M 90M 89M 79M 161M
totalCurrentAssets 4 037M 3 467M 3 684M 3 138M 3 135M 3 002M 3 040M 3 155M 3 202M
propertyPlantEquipmentNet 5 358M 5 440M 5 513M 5 575M 5 607M 5 706M 5 833M 5 923M 5 962M
goodwill 7 228M 7 201M 7 230M 7 113M 7 088M 7 106M 7 090M 7 077M 7 023M
intangibleAssets 198M 191M 201M 203M 185M 192M 187M 183M 180M
goodwillAndIntangibleAssets 7 425M 7 393M 7 431M 7 316M 7 274M 7 298M 7 277M 7 259M 7 202M
longTermInvestments 430M 537M 540M 594M 611M 639M 286M 275M 287M
taxAssets 51M 694M 720M 760M 0 760M 771 087M 0 0
otherNonCurrentAssets 202M -505M -457M 237M 302M -446M -770 796M 316M 308M
totalNonCurrentAssets 13 467M 13 559M 13 747M 14 482M 13 793M 13 957M 13 688M 13 773M 13 759M
otherAssets 0 0 0 0 0 0 0 0 0
totalAssets 17 504M 17 026M 17 431M 17 619M 16 929M 16 959M 16 728M 16 928M 16 962M
accountPayables 488M 494M 490M 515M 435M 428M 448M 480M 417M
shortTermDebt 701M 943M 529M 518M 502M 496M 637M 627M 611M
taxPayables 21M 25M 83M 29M 22M 32M 65M 18M 10M
deferredRevenue 0 25M 705M 29M 793M 662M 0 783M 819 073M
otherCurrentLiabilities 1 734M 1 533M 860M 1 581M 808M 818M 1 480M 730M -817 564M
totalCurrentLiabilities 2 944M 2 995M 2 583M 2 642M 2 538M 2 403M 2 565M 2 620M 2 537M
longTermDebt 11 497M 10 733M 11 312M 8 051M 10 627M 10 983M 10 873M 11 196M 11 426M
deferredRevenueNonCurrent 0 2 526M 0 2 547M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 660M 694M 720M 1 452M 754M 760M 771M 783M 819M
otherNonCurrentLiabilities 183M 179M 180M 183M 185M 183M 100M 105M -807 750M
totalNonCurrentLiabilities 12 340M 11 606M 12 212M 12 234M 11 566M 11 926M 11 744M 12 084M 12 352M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 2 642M 2 930M 2 713M 2 547M 2 736M 2 779M 2 850M 2 898M 2 955M
totalLiabilities 15 284M 14 601M 14 795M 14 876M 14 104M 14 329M 14 309M 14 703M 14 889M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 90 000 90 000 90 000 89 000 91 000 91 000 91 000 90 000 98 000
retainedEarnings 1 275M 1 061M 838M 598M 715M 469M 290M 174M 847M
accumulatedOtherComprehensiveIncomeLoss -162M -195M -100M -52M -69M -7M -55M -69M -136M
othertotalStockholdersEquity -726M -233M 188M 510M 553M 556M 590M 607M -179M
totalStockholdersEquity 387M 633M 926M 1 056M 1 199M 1 017M 825M 712M 533M
totalEquity 2 220M 2 425M 2 636M 2 743M 2 825M 2 630M 2 419M 712M 533M
totalLiabilitiesAndStockholdersEquity 17 504M 17 026M 17 431M 17 619M 16 929M 16 959M 16 728M 16 928M 16 962M
minorityInterest 1 833M 1 792M 1 710M 1 687M 1 625M 1 612M 1 593M 1 512M 0
totalLiabilitiesAndTotalEquity 17 504M 17 026M 17 431M 17 619M 16 929M 16 959M 16 728M 16 928M 16 962M
totalInvestments 451M 557M 551M 605M 622M 652M 291 712M 353M 361M
totalDebt 12 198M 11 676M 11 841M 11 116M 11 129M 11 478M 11 509M 11 822M 12 037M
netDebt 11 127M 11 172M 11 496M 10 652M 10 680M 11 151M 11 192M 11 578M 11 669M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol DVA DVA DVA DVA DVA DVA DVA DVA DVA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066 927 066
fillingDate 2024-10-29 2024-08-06 2024-05-02 2024-02-14 2023-11-07 2023-08-03 2023-05-08 2023-02-22 2022-10-31
acceptedDate 2024-10-29 17:04:29 2024-08-06 17:03:37 2024-05-02 16:12:00 2024-02-14 17:01:00 2023-11-07 17:08:38 2023-08-03 17:07:32 2023-05-08 17:03:28 2023-02-22 17:19:41 2022-10-28 18:02:55
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 296M 223M 306M 151M 309M 246M 171M 127M 165M
depreciationAndAmortization 187M 176M 187M 195M 188M 184M 178M 194M 194M
deferredIncomeTax -25M -25M -3M -22M -2M -13M -4M -40M -45M
stockBasedCompensation 27M 24M 25M 30M 27M 30M 25M 18M 28M
changeInWorkingCapital 272M 277M -640M 11M 106M -5M 83M 31M 320M
accountsReceivables 17M 368M -561M 54M -23M 60M 82M -13M -4M
inventory -2M 20M 2M -32M -5M -3M 3M -1M 2M
accountsPayables -4M -25M -14M 61M 7M -20M -21M 49M 14M
otherWorkingCapital 261M -87M -74M -72M 127M -42M 19M -4M 307M
otherNonCashItems 54M 140M 8M 122M 32M 8M 9M 15M 48M
netCashProvidedByOperatingActivities 810M 803M -135M 487M 661M 450M 463M 344M 711M
investmentsInPropertyPlantAndEquipment -139M -125M -121M -159M -137M -124M -148M -194M -144M
acquisitionsNet 5M -78M -106M -14M -8M -268M -8M -17M -39M
purchasesOfInvestments -24M -676 000 -3M -10M -327 000 -7M -30M -35M -5M
salesMaturitiesOfInvestments 15M 7M 5M 12M 57 000 44M 54M 30M 32M
otherInvestingActivites 0 6M 7M 6M 5M 8M 15M 3M 2M
netCashUsedForInvestingActivites -143M -196M -215M -171M -140M -347M -117M -213M -154M
debtRepayment 545M -141M -736M -45M -645M -1 467M -881M -847M -716M
commonStockIssued 0 0 0 0 0 0 0 0 0
commonStockRepurchased -434M -361M -337M -272M 2M -36M -8M 5M -179M
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -122M -30M -79M -85M 248M 1 405M 613M 611M 450M
netCashUsedProvidedByFinancingActivities -11M -533M 319M -402M -395M -97M -276M -231M -445M
effectOfForexChangesOnCash -654 000 -1M -3M 6M -4M 5M 2M -23M -5M
netChangeInCash 655M 72M -34M -80M 123M 11M 72M -123M 106M
cashAtEndOfPeriod 1 159M 503M 431M 465M 545M 422M 411M 339M 462M
cashAtBeginningOfPeriod 503M 431M 465M 545M 422M 411M 339M 462M 356M
operatingCashFlow 810M 803M -135M 487M 661M 450M 463M 344M 711M
capitalExpenditure -139M -125M -121M -159M -137M -124M -148M -194M -144M
freeCashFlow 671M 678M -256M 328M 524M 326M 315M 150M 567M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-10-29 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-13 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-08 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-10-28 ET (fiscal 2022 q3)
2022 q2
2022-08-01 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-29 20:05 ET
DaVita Inc. 3rd Quarter 2024 Results
2024-10-28 15:05 ET
DaVita Emphasizes Commitment to Whole-Person Care with Investment in National Kidney Foundation PEERS Program
2024-10-22 12:00 ET
DaVita celebrates kidney care community achievements in year one of largest-ever value-based care program
2024-10-17 17:00 ET
DaVita Appoints Jessica Hergenreter as Chief People Officer
2024-10-11 19:58 ET
DaVita Opens its Doors to Anyone in Florida Needing Dialysis After Hurricane Milton
2024-10-09 17:47 ET
DaVita Inc. Schedules 3rd Quarter 2024 Investor Conference Call
2024-10-08 17:38 ET
DaVita Prepares Thousands of Dialysis Patients for Hurricane Milton
2024-09-17 13:00 ET
DaVita Accelerates Commitment to Community Health with Nationwide Tour
2024-09-13 12:00 ET
DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role
2024-08-08 13:16 ET
DaVita Inc. Announces Offering of $1.0 Billion Senior Notes
2024-08-06 20:05 ET
DaVita Inc. 2nd Quarter 2024 Results
2024-07-18 18:00 ET
DaVita Inc. Schedules 2nd Quarter 2024 Investor Conference Call
2024-05-14 13:00 ET
DaVita Celebrates Corporate Citizenship Achievements with Release of 2023 Community Care Report
2024-05-13 13:00 ET
DaVita Appoints New Chief Information Officer
2024-05-09 22:15 ET
DaVita Inc. to Participate in the BofA Securities 2024 Health Care Conference
2024-05-09 14:00 ET
DaVita Honors 54 Nephrology Nurses with DAISY Awards
2024-05-02 20:05 ET
DaVita Inc. 1st Quarter 2024 Results
2024-04-22 13:00 ET
DaVita's Global Operations Powered by 100% Renewable Energy
2024-04-17 23:31 ET
DaVita Inc. Schedules 1st Quarter 2024 Investor Conference Call
2024-04-10 13:00 ET
DaVita Announces Dennis Pullin to its Board of Directors
2024-03-11 20:40 ET
The American Diabetes Association and DaVita Strengthen Alliance to Tackle Chronic Disease Head-On
2024-03-08 22:20 ET
DaVita Inc. to Participate in the Barclays Global Healthcare Conference 2024
2024-03-05 14:00 ET
DaVita enters into agreement to expand operations in Brazil and Colombia, enter Chile and Ecuador
2024-03-01 00:19 ET
DaVita Inc. to Participate in the TD Cowen's Health Care Conference 2024
2024-02-13 21:08 ET
DaVita Inc. 4th Quarter 2023 Results
2024-01-23 19:00 ET
DaVita Inc. Schedules 4th Quarter 2023 Investor Conference Call
2023-12-19 15:00 ET
DaVita Giving Foundation Invests $1 Million in Western Governors University to Support Nursing Students
2023-11-30 15:00 ET
DaVita's 'Move It With Purpose' Event Achieves Record-Breaking Participation to Support Life-Saving Care
2023-11-07 21:05 ET
DaVita Inc. 3rd Quarter 2023 Results
2023-11-02 16:05 ET
DaVita Unveils New Research to Drive Health Equity and Improve Care Quality during Annual American Society of Nephrology Meeting
2023-10-18 16:00 ET
DaVita Collaborates with Google Cloud to Develop Customized Clinical Operating System Designed to Transform Kidney Care
2023-10-17 22:26 ET
DaVita Inc. Schedules 3rd Quarter 2023 Investor Conference Call
2023-10-12 12:30 ET
DaVita Statement on GLP-1 and Potential Implications on Chronic Kidney Disease
2023-09-13 12:15 ET
DaVita launches community health tour to provide free kidney screenings and education coast-to-coast
2023-09-11 20:54 ET
DaVita Inc. to Participate in Fireside Chat with UBS
2023-08-03 20:05 ET
DaVita Inc. 2nd Quarter 2023 Results
2023-07-13 21:05 ET
DaVita Announces Wendy Schoppert to Join its Board of Directors
2023-07-13 20:00 ET
DaVita Inc. Schedules 2nd Quarter 2023 Investor Conference Call
2023-05-10 10:02 ET
DaVita Recognizes Nephrology Nurses with DAISY Award
2023-05-08 20:05 ET
DaVita Inc. 1st Quarter 2023 Results
2023-05-04 10:02 ET
DaVita Celebrates Corporate Citizenship Achievements, Releases its 2022 Community Care Report
2023-05-02 19:51 ET
DaVita Inc. to Participate in the BofA Securities Healthcare Conference 2023
2023-04-18 17:30 ET
DaVita Inc. Schedules 1st Quarter 2023 Investor Conference Call
2023-04-04 12:04 ET
LEX FERENDA LITIGATION FUNDING EXPANDS TO DENVER; ANNOUNCES ADDITION OF PROMINENT LITIGATOR AND IN-HOUSE ATTORNEY ANDREW KELLEY
2023-03-13 19:34 ET
DaVita Inc. to Participate in the Barclays 2023 Global Healthcare Conference
2023-02-22 21:05 ET
DaVita Inc. 4th Quarter 2022 Results
2023-02-01 10:00 ET
DaVita Inc. Schedules 4th Quarter 2022 Investor Conference Call
2023-01-31 11:02 ET
DaVita Emphasized Holistic Care for Kidney Patients and Teammates in 2022
2022-12-20 11:02 ET
DaVita's Move It with Purpose Event Raises Funds for Bridge of Life
2022-11-03 10:02 ET
DaVita Clinical Research Showcases Chronic Kidney Disease and Rare Disease Network, Presents New Research Findings at Kidney Week 2022
2022-10-28 10:30 ET
DaVita Inc. 3rd Quarter 2022 Results
2022-10-14 09:00 ET
DaVita Inc. Schedules 3rd Quarter 2022 Investor Conference Call
2022-10-10 10:02 ET
The DaVita Giving Foundation Provides $1.4 Million Grant Toward Addressing Food Insecurity
2022-09-13 21:02 ET
DaVita Announces Adam H. Schechter to Join its Board of Directors
2022-08-01 20:05 ET
DaVita Inc. 2nd Quarter 2022 Results
2022-07-25 14:11 ET
American Diabetes Association Focuses on Prevention of Kidney Disease through Collaboration with DaVita
2022-07-18 08:05 ET
DaVita Inc. Schedules 2nd Quarter 2022 Investor Conference Call
2022-06-22 20:02 ET
Rockwell Medical Provides Corporate and Clinical Update
2022-06-22 15:06 ET
DaVita Inc. Schedules Special Investor Conference Call
2022-05-10 10:02 ET
DaVita Honors Extraordinary Nurses with DAISY Awards
2022-05-09 10:02 ET
DaVita Inc. to Participate in the Bank of America Securities 2022 Healthcare Conference
2022-05-05 20:05 ET
DaVita Inc. 1st Quarter 2022 Results
2022-05-03 10:02 ET
DaVita Celebrates 2021 ESG, Corporate Social Responsibility Achievements
2022-04-21 08:05 ET
DaVita Inc. Schedules 1st Quarter 2022 Investor Conference Call
2022-04-11 13:00 ET
Rockwell Medical Expands Partnership with DaVita
2022-04-07 22:01 ET
DaVita Announces Jason M. Hollar to Join its Board of Directors
2022-04-04 17:53 ET
New Research Affirms Increase in Access, Equity of COVID-19 Vaccines Administered in Dialysis Centers
2022-02-17 11:04 ET
DaVita Clinical Research Study Finds Efficacy of Common COVID-19 Vaccines at Parity for Kidney Patients
2022-02-16 11:02 ET
DaVita Kidney Care Appoints New Chief Medical Officer of Home Modalities
2022-02-14 11:02 ET
DaVita expands paid leave to support teammates choosing to be living organ donors
2022-02-10 21:05 ET
DaVita Inc. 4th Quarter 2021 Results
2022-01-27 21:05 ET
DaVita Inc. Schedules 4th Quarter 2021 Investor Conference Call
2022-01-19 11:02 ET
Kidney Doctors, Transplant Providers Work with DaVita in New Government Program to Help Improve the Lives of Medicare Patients with Kidney Disease
2022-01-18 11:02 ET
DaVita Acquires MedSleuth, Deepens Efforts to Improve Transplant Experience
2022-01-12 11:02 ET
DaVita Teammates Transformed Care for Thousands of Patients in 2021
2022-01-06 11:02 ET
DaVita Celebrates 10 Years of Kidney Smart® Educational Programming
2021-12-16 11:02 ET
DaVita Integrated Kidney Care Expands Clinical Leadership Team
2021-12-09 11:02 ET
DaVita's North American Operations Now Powered by 100% Renewable Energy
2021-11-30 11:02 ET
15th Annual Tour DaVita Raises Nearly $1 Million for Bridge of Life
2021-11-29 11:01 ET
DaVita Clinical Research Study Indicates Effectiveness of mRNA COVID-19 Vaccines in Dialysis Patients
2021-11-04 10:04 ET
DaVita Clinical Research to Present New Findings at American Society of Nephrology Kidney Week 2021
2021-11-01 10:01 ET
The American Diabetes Association® and DaVita Raise Awareness about the Link between Diabetes and Kidney Disease during American Diabetes Month®
2021-10-28 20:05 ET
DaVita Inc. 3rd Quarter 2021 Results
2021-10-19 10:01 ET
DaVita Inc. Schedules Virtual Capital Markets Day for November 16, 2021
2021-10-19 10:00 ET
DaVita Inc. Schedules 3rd Quarter 2021 Investor Conference Call
2021-10-11 10:02 ET
DaVita Climate Action Goals Approved by the Science Based Target Initiative
2021-09-16 10:02 ET
DaVita Kidney Care Names New Chief Nursing Officer
2021-09-09 20:02 ET
DaVita Announces Dr. Gregory Moore to Join its Board of Directors
2021-08-03 20:05 ET
DaVita Inc. 2nd Quarter 2021 Results
2021-07-21 08:00 ET
DaVita Inc. Schedules 2nd Quarter 2021 Investor Conference Call
2021-06-10 12:04 ET
DaVita and the National Kidney Foundation Join Forces to Improve Health Equity in Kidney Transplantation
2021-06-02 10:07 ET
Virtual Support Groups Create Community for DaVita Home Dialysis Patients
2021-05-13 10:02 ET
Extraordinary Nurses at DaVita Kidney Care Honored with DAISY Awards
2021-05-10 10:01 ET
DaVita to Further Elevate its Home Dialysis Care Experience with New Baxter Technology
2021-04-29 20:05 ET
DaVita Inc. 1st Quarter 2021 Results
2021-04-27 10:02 ET
DaVita Solidifies Commitment to ESG, Sets 2025 Goals
2021-04-22 20:05 ET
DaVita Inc. Schedules 1st Quarter 2021 Investor Conference Call
2021-04-12 14:00 ET
Blue Cross and Blue Shield of Minnesota Launches Program with DaVita's VillageHealth to Improve Care for Members with Kidney Disease
2021-03-29 10:05 ET
DaVita Shares Strategy for Achieving a Diverse Community Where Everyone Belongs
2021-03-25 15:00 ET
DaVita Statement on Government's Nationwide Program to Vaccinate Dialysis Patients
2021-03-23 12:00 ET
DaVita Kidney Care Expands Use of NxStage Home Hemodialysis Machines from Fresenius Medical Care
2021-03-16 12:00 ET
NephroSant Announces $16 Million Series A, Led by DaVita Venture Group
2021-03-09 08:00 ET
DaVita Inc. to Participate in the 2021 Barclays Global Healthcare Conference
2021-02-24 23:00 ET
DaVita Inc. Announces Upsize and Pricing of Add-On Offering of $1 Billion Senior Notes
2021-02-24 12:44 ET
DaVita Inc. Announces Add-On Offering of $750 Million Senior Notes
2021-02-11 21:06 ET
DaVita Inc. 4th Quarter 2020 Results
2021-01-29 10:48 ET
DaVita Inc. Schedules 4th Quarter 2020 Investor Conference Call
2020-12-22 11:07 ET
DaVita Celebrates 100,000 Patients Receiving Kidney Transplants
2020-11-23 11:04 ET
14th Annual Tour DaVita Raises Nearly $1 Million for Bridge of Life
2020-11-04 07:13 ET
DaVita Responds to Proposition 23 in California
2020-10-29 20:01 ET
DaVita Inc. 3rd Quarter 2020 Results
2020-10-22 13:01 ET
DaVita Clinical Research to Present New Findings at American Society of Nephrology Kidney Week 2020
2020-10-15 20:52 ET
DaVita Inc. Schedules 3rd Quarter 2020 Investor Conference Call
2020-09-17 10:00 ET
DaVita Announces Final Results Of Self-Tender Offer
2020-09-15 10:30 ET
DaVita Announces Preliminary Results of Self-Tender Offer
2020-09-08 10:00 ET
DaVita Announces Shawn Guertin Will Join its Board of Directors
2020-08-27 20:07 ET
DaVita Opens Its Doors to Hurricane Laura Evacuees Needing Dialysis
2020-08-20 10:07 ET
Clinical Research Trials Underway to Study COVID-19 Impact on Dialysis Patients
2020-08-17 08:00 ET
DaVita Commences Self-Tender Offer To Purchase For Cash Shares Of Its Common Stock
2020-08-13 10:17 ET
DaVita Expands Initiative to Advance Nursing Education
2020-08-11 08:30 ET
DaVita Announces Paula A. Price to Join its Board of Directors
2020-08-06 11:27 ET
DaVita Inc. Announces Offering of $1.5 Billion Senior Notes
2020-07-30 20:01 ET
DaVita Inc. 2nd Quarter 2020 Results
2020-07-15 20:01 ET
DaVita Inc. Schedules 2nd Quarter 2020 Investor Conference Call
2020-05-26 12:30 ET
DaVita Inc. Announces Offering of $1.75 Billion Senior Notes
2020-05-05 20:01 ET
DaVita Inc. COVID-19 Response Efforts and 1st Quarter 2020 Results
2020-04-29 10:33 ET
DaVita Reports on 2019 Corporate Social Responsibility Initiatives
2020-04-13 10:00 ET
DaVita Inc. Provides Commentary on the COVID-19 Pandemic
2020-04-13 09:55 ET
DaVita Inc. Schedules 1st Quarter 2020 Investor Conference Call
2020-03-31 21:01 ET
Focus on Patient Care Brings Industry Together to Fight Crisis
2020-03-11 10:14 ET
DaVita Hospital Services Group Names New Chief Medical Officer
2020-02-10 21:01 ET
DaVita Inc. 4th Quarter 2019 Results
2020-01-29 11:00 ET
DaVita Inc. Schedules 4th Quarter 2019 Investor Conference Call
2020-01-22 11:31 ET
DaVita Celebrates 2019 Achievements
2019-11-05 21:01 ET
DaVita Inc. 3rd Quarter 2019 Results
2019-10-29 06:01 ET
DaVita Selects its Next Chief Accounting Officer
2019-10-24 10:42 ET
DaVita Inc. Schedules 3rd Quarter 2019 Investor Conference Call
2019-03-16 00:45 ET
Kay Properties Completes DST 1031 Offering in Baltimore, Maryland
2019-03-01 11:00 ET
Empowering the Kidney Care Community: Kidney Disease Treatment Options to Fit Many Lifestyles
2019-02-21 11:01 ET
DaVita Celebrates 12 Consecutive Years Among FORTUNE® Magazine's World's Most Admired Companies®
2019-02-13 21:29 ET
DaVita Inc. 4th Quarter 2018 Results

SEC forms

Show financial reports only

SEC form 10
2025-02-13 17:25 ET
DaVita reported for 2024 q4
SEC form 8
2025-02-13 16:07 ET
DaVita published news for 2024 q4
SEC form 8
2025-02-13 16:07 ET
DaVita published news for 2024 q4
SEC form 10
2025-02-13 00:00 ET
DaVita published news for 2024 q4
SEC form 10
2024-10-29 17:04 ET
DaVita published news for 2024 q3
SEC form 8
2024-10-29 16:08 ET
DaVita published news for 2024 q3
SEC form 8
2024-10-29 16:08 ET
DaVita reported for 2024 q3
SEC form 10
2024-10-29 00:00 ET
DaVita published news for 2024 q3
SEC form 10
2024-08-06 17:03 ET
DaVita published news for 2024 q2
SEC form 8
2024-08-06 16:10 ET
DaVita reported for 2024 q2
SEC form 8
2024-08-06 16:10 ET
DaVita published news for 2024 q2
SEC form 10
2024-08-06 00:00 ET
DaVita published news for 2024 q2
SEC form 10
2024-05-02 16:12 ET
DaVita reported for 2024 q1
SEC form 8
2024-05-02 16:10 ET
DaVita published news for 2024 q1
SEC form 8
2024-05-02 16:10 ET
DaVita published news for 2024 q1
SEC form 10
2024-05-02 00:00 ET
DaVita published news for 2024 q1
SEC form 10
2024-02-14 00:00 ET
DaVita reported for 2023 q4
SEC form 8
2024-02-13 00:00 ET
DaVita published news for 2023 q4
SEC form 8
2024-02-13 00:00 ET
DaVita published news for 2023 q4
SEC form 10
2023-11-07 17:08 ET
DaVita published news for 2023 q3
SEC form 8
2023-11-07 16:11 ET
DaVita reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
DaVita published news for 2023 q3
SEC form 10
2023-08-03 17:07 ET
DaVita published news for 2023 q2
SEC form 6
2023-08-03 16:08 ET
DaVita reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
DaVita published news for 2023 q2
SEC form 8
2023-08-03 00:00 ET
DaVita published news for 2023 q2
SEC form 6
2023-07-25 16:42 ET
DaVita published news for 2023 q2
SEC form 6
2023-07-20 18:32 ET
DaVita published news for 2023 q2
SEC form 6
2023-07-13 17:16 ET
DaVita published news for 2023 q2
SEC form 6
2023-06-15 16:28 ET
DaVita published news for 2023 q1
SEC form 6
2023-06-08 16:47 ET
DaVita published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
DaVita published news for 2023 q1
SEC form 8
2023-05-08 00:00 ET
DaVita published news for 2023 q1
SEC form 6
2023-03-21 06:22 ET
DaVita published news for 2022 q4
SEC form 10
2023-02-22 17:19 ET
DaVita published news for 2022 q4
SEC form 6
2023-02-22 16:09 ET
DaVita published news for 2022 q4
SEC form 10
2023-02-22 00:00 ET
DaVita reported for 2022 q4
SEC form 8
2023-02-22 00:00 ET
DaVita reported for 2022 q4
SEC form 10
2022-10-31 00:00 ET
DaVita reported for 2022 q3
SEC form 10
2022-10-28 18:02 ET
DaVita published news for 2022 q3
SEC form 6
2022-10-28 06:33 ET
DaVita published news for 2022 q3
SEC form 8
2022-10-28 00:00 ET
DaVita reported for 2022 q3
SEC form 6
2022-10-18 16:48 ET
DaVita published news for 2022 q3
SEC form 6
2022-09-29 18:38 ET
DaVita published news for 2022 q2
SEC form 6
2022-09-13 17:17 ET
DaVita published news for 2022 q2
SEC form 10
2022-08-01 17:07 ET
DaVita published news for 2022 q2
SEC form 6
2022-08-01 16:10 ET
DaVita published news for 2022 q2
SEC form 8
2022-08-01 00:00 ET
DaVita reported for 2022 q2
SEC form 10
2022-08-01 00:00 ET
DaVita reported for 2022 q2
SEC form 6
2022-06-21 16:38 ET
DaVita published news for 2022 q1
SEC form 6
2022-06-14 16:29 ET
DaVita published news for 2022 q1
SEC form 6
2022-05-26 06:45 ET
DaVita published news for 2022 q1
SEC form 6
2022-05-16 06:19 ET
DaVita published news for 2022 q1
SEC form 10
2022-05-05 17:07 ET
DaVita published news for 2022 q1
SEC form 6
2022-05-05 16:08 ET
DaVita published news for 2022 q1
SEC form 10
2022-05-05 00:00 ET
DaVita reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
DaVita reported for 2022 q1
SEC form 6
2022-04-25 06:16 ET
DaVita published news for 2022 q1
SEC form 6
2022-04-07 18:34 ET
DaVita published news for 2022 q1
SEC form 10
2022-02-11 16:07 ET
DaVita published news for 2021 q4
SEC form 10
2022-02-11 00:00 ET
DaVita published news for 2021 q4
SEC form 6
2022-02-10 16:08 ET
DaVita published news for 2021 q4
SEC form 8
2022-02-10 00:00 ET
DaVita published news for 2021 q4
SEC form 6
2022-02-09 17:03 ET
DaVita published news for 2021 q4
SEC form 6
2021-12-17 17:16 ET
DaVita published news for 2021 q3
SEC form 10
2021-10-28 17:04 ET
DaVita published news for 2021 q3
SEC form 6
2021-10-28 16:09 ET
DaVita published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
DaVita published news for 2021 q3
SEC form 10
2021-10-28 00:00 ET
DaVita published news for 2021 q3
SEC form 6
2021-09-16 16:56 ET
DaVita published news for 2021 q2
SEC form 6
2021-09-09 16:48 ET
DaVita published news for 2021 q2
SEC form 10
2021-08-03 17:04 ET
DaVita published news for 2021 q2
SEC form 6
2021-08-03 16:09 ET
DaVita published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
DaVita published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
DaVita published news for 2021 q2
SEC form 6
2021-06-23 20:08 ET
DaVita published news for 2021 q1
SEC form 6
2021-06-14 16:58 ET
DaVita published news for 2021 q1
SEC form 6
2021-05-21 16:38 ET
DaVita published news for 2021 q1
SEC form 10
2021-04-29 17:06 ET
DaVita published news for 2021 q1
SEC form 6
2021-04-29 16:09 ET
DaVita published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
DaVita published news for 2021 q1
SEC form 10
2021-04-29 00:00 ET
DaVita published news for 2021 q1
SEC form 6
2021-04-23 16:49 ET
DaVita published news for 2021 q1
SEC form 6
2021-03-09 06:04 ET
DaVita published news for 2020 q4
SEC form 6
2021-02-26 16:25 ET
DaVita published news for 2020 q4
SEC form 6
2021-02-24 18:11 ET
DaVita published news for 2020 q4
SEC form 6
2021-02-24 08:17 ET
DaVita published news for 2020 q4
SEC form 10
2021-02-12 16:07 ET
DaVita published news for 2020 q4
SEC form 6
2021-02-11 16:10 ET
DaVita published news for 2020 q4
SEC form 6
2020-12-10 16:48 ET
DaVita published news for 2020 q3
SEC form 6
2020-11-13 16:16 ET
DaVita published news for 2020 q3
SEC form 10
2020-10-29 17:05 ET
DaVita published news for 2020 q3
SEC form 6
2020-10-29 16:14 ET
DaVita published news for 2020 q3
SEC form 6
2020-10-05 06:25 ET
DaVita published news for 2020 q3